Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
Sign Up to like & getrecommendations! Published in 2018 at "Revista Espanola De Enfermedades Digestivas"
DOI: 10.17235/reed.2018.5456/2018
Abstract: : In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing… read more here.
Keywords: position statement; position; update sepd; sepd position ... See more keywords